• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一位 47 岁男性,因慢性肾衰竭服用碳酸镧片导致高磷血症,现出现部分性大肠梗阻急症。

A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.

机构信息

Department of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

出版信息

Am J Case Rep. 2023 Nov 23;24:e942113. doi: 10.12659/AJCR.942113.

DOI:10.12659/AJCR.942113
PMID:37994013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11009886/
Abstract

BACKGROUND Hyperphosphatemia is a complication of chronic renal failure (CRF) due to reduction in the glomerular filtration rate. Lanthanum carbonate is a commonly used phosphate binder for patients with CRF and hyperphosphatemia, but has adverse effects if patients are not monitored. This report is of a 47-year-old man with hyperphosphatemia due to CRF treated with lanthanum carbonate tablets who presented acutely with partial large bowel obstruction. The incidence of lanthanum carbonate causing intestinal obstruction is rare, and few cases in the literature have described the course of the disease in detail. CASE REPORT A 47-year-old man diagnosed with diabetic nephropathy underwent hemodialysis treatment and was prescribed 0.5 g/day of chewable lanthanum carbonate tablets. After taking lanthanum carbonate for 5 months, the patient experienced symptoms of decreased bowel movements and exhaustion, which progressively worsened. Abdominal computed tomography (CT) revealed multiple hyperdensities in the large bowel, indicating the presence of lanthanum deposition. Lanthanum carbonate was promptly discontinued. After undergoing enema and catharsis treatment, the large bowel obstruction was relieved, and the hyperdensities in the abdominal CT disappeared. The colonoscopy and histologic examination revealed ulcerations and inflammatory changes in the large bowel mucosa. CONCLUSIONS This report highlights the rare association between the use of lanthanum carbonate tablets and intestinal obstruction. Healthcare providers should enhance their vigilance regarding lanthanum carbonate-induced serious gastrointestinal adverse reactions and actively seek to detect lanthanum deposition by abdominal CT or radiography (X-ray). After the occurrence of lanthanum deposition, drug withdrawal and promotion of defecation are primary treatment methods.

摘要

背景

高磷血症是慢性肾衰竭(CRF)的并发症,由于肾小球滤过率降低所致。碳酸镧是 CRF 和高磷血症患者常用的磷结合剂,但如果不进行监测,可能会产生不良反应。本报告介绍了 1 例因 CRF 接受碳酸镧片治疗而发生高磷血症的 47 岁男性患者,该患者突发部分大肠梗阻。碳酸镧引起肠梗阻的发生率较低,文献中很少有病例详细描述疾病过程。

病例报告

1 例 47 岁男性,诊断为糖尿病肾病,行血液透析治疗,处方 0.5 g/天的咀嚼碳酸镧片。服用碳酸镧 5 个月后,患者出现便秘和乏力症状,且逐渐加重。腹部计算机断层扫描(CT)显示大肠多处高密度影,提示镧沉积。立即停用碳酸镧。经灌肠和通便治疗后,大肠梗阻缓解,腹部 CT 高密度影消失。结肠镜和组织学检查显示大肠黏膜溃疡和炎症改变。

结论

本报告强调了碳酸镧片使用与肠梗阻之间罕见的关联。医疗保健提供者应提高对碳酸镧引起的严重胃肠道不良反应的警惕性,并积极通过腹部 CT 或 X 射线检查(X 射线)检测镧沉积。发生镧沉积后,停药和促进排便是主要的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/eb849c4b23cb/amjcaserep-24-e942113-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/f184f5e5fc6d/amjcaserep-24-e942113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/e120c11d1b72/amjcaserep-24-e942113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/eb849c4b23cb/amjcaserep-24-e942113-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/f184f5e5fc6d/amjcaserep-24-e942113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/e120c11d1b72/amjcaserep-24-e942113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/eb849c4b23cb/amjcaserep-24-e942113-g003.jpg

相似文献

1
A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.一位 47 岁男性,因慢性肾衰竭服用碳酸镧片导致高磷血症,现出现部分性大肠梗阻急症。
Am J Case Rep. 2023 Nov 23;24:e942113. doi: 10.12659/AJCR.942113.
2
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.碳酸镧与碳酸钙治疗高磷血症对接受血液透析的慢性肾脏病患者心血管事件的影响:LANDMARK随机临床试验
JAMA. 2021 May 18;325(19):1946-1954. doi: 10.1001/jama.2021.4807.
3
Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis.透析患者体内碳酸镧水合物导致 CT 图像出现束硬化伪影。
Jpn J Radiol. 2010 May;28(4):322-4. doi: 10.1007/s11604-010-0426-0. Epub 2010 May 29.
4
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.碳酸镧对日本接受血液透析的慢性肾病患者高磷血症的一年疗效及安全性
Ther Apher Dial. 2010 Feb;14(1):12-9. doi: 10.1111/j.1744-9987.2009.00697.x.
5
[Lanthanum carbonate in clinical practice].[碳酸镧在临床实践中]
Nefrologia. 2008;28 Suppl 5:11-4.
6
Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.碳酸镧可有效控制接受血液透析患者的血清磷水平,且不影响血清钙水平。
Ther Apher Dial. 2008 Feb;12(1):55-61. doi: 10.1111/j.1744-9987.2007.00541.x.
7
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.在日本高磷血症血液透析患者中,碳酸镧与碳酸钙作为磷结合剂的多中心前瞻性随机双盲对照研究。
Clin Nephrol. 2008 Nov;70(5):404-10. doi: 10.5414/cnp70404.
8
Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach.7例胃内磷酸镧沉积患者的临床特征
Intern Med. 2017 Aug 15;56(16):2089-2095. doi: 10.2169/internalmedicine.8720-16. Epub 2017 Aug 1.
9
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.高剂量碳酸镧可在减少片剂服用量的情况下控制血清磷水平,受到患者和医生的青睐:一项多中心研究。
Clin J Am Soc Nephrol. 2008 Sep;3(5):1437-45. doi: 10.2215/CJN.04741107. Epub 2008 Jun 25.
10
Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.碳酸镧对韩国持续性非卧床腹膜透析患者磷酸盐控制的影响:一项随机前瞻性研究。
Clin Nephrol. 2013 Feb;79(2):136-42. doi: 10.5414/CN107362.

引用本文的文献

1
Therapeutic effectiveness and safety profile of lanthanum carbonate in conjunction with calcium carbonate for managing hyperphosphatemia in hemodialysis patients: a meta-analysis of randomized controlled trials.碳酸镧联合碳酸钙治疗血液透析患者高磷血症的疗效及安全性分析:一项随机对照试验的荟萃分析
Am J Transl Res. 2024 Nov 15;16(11):6980-6990. doi: 10.62347/WXBL2590. eCollection 2024.

本文引用的文献

1
Lanthanum Carbonate Opacities-A Systematic Review.碳酸镧混浊——一项系统评价
Diagnostics (Basel). 2022 Feb 11;12(2):464. doi: 10.3390/diagnostics12020464.
2
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.碳酸镧治疗终末期肾病患者高磷血症的安全性、有效性及耐受性的临床评估
Ther Clin Risk Manag. 2020 Sep 15;16:871-880. doi: 10.2147/TCRM.S196805. eCollection 2020.
3
Review of the diagnosis of gastrointestinal lanthanum deposition.
胃肠道镧沉积的诊断评价。
World J Gastroenterol. 2020 Apr 7;26(13):1439-1449. doi: 10.3748/wjg.v26.i13.1439.
4
Phosphate binders in chronic kidney disease: an updated narrative review of recent data.慢性肾脏病中的磷酸盐结合剂:近期数据的更新叙述性综述。
J Nephrol. 2020 Jun;33(3):497-508. doi: 10.1007/s40620-019-00689-w. Epub 2019 Dec 21.
5
Strategies for Phosphate Control in Patients With CKD.慢性肾脏病患者磷酸盐控制策略
Kidney Int Rep. 2019 Jun 20;4(8):1043-1056. doi: 10.1016/j.ekir.2019.06.002. eCollection 2019 Aug.
6
Starry-sky bowels.星空样肠管
Int J Colorectal Dis. 2018 Dec;33(12):1807-1808. doi: 10.1007/s00384-018-3173-9. Epub 2018 Oct 2.
7
Lanthanum carbonate: safety data after 10 years.碳酸镧:10年后的安全性数据。
Nephrology (Carlton). 2016 Dec;21(12):987-994. doi: 10.1111/nep.12864.
8
Lanthanum Deposition Is Frequently Observed in the Gastric Mucosa of Dialysis Patients With Lanthanum Carbonate Therapy: A Clinicopathologic Study of 13 Cases, Including 1 Case of Lanthanum Granuloma in the Colon and 2 Nongranulomatous Gastric Cases.接受碳酸镧治疗的透析患者胃黏膜中常观察到镧沉积:13例临床病理研究,包括1例结肠镧肉芽肿和2例非肉芽肿性胃病例。
Int J Surg Pathol. 2016 Feb;24(1):89-92. doi: 10.1177/1066896915613434. Epub 2015 Oct 21.
9
Lanthanum, constipation, bafflying X-rays and a perforated colonic diverticulum.镧、便秘、令人困惑的X光检查与结肠憩室穿孔
Clin Kidney J. 2012 Aug;5(4):331-3. doi: 10.1093/ckj/sfs073. Epub 2012 Jul 6.
10
Fecalith formation and colonic perforation after lanthanum carbonate granules administration.服用碳酸镧颗粒后粪石形成及结肠穿孔。
Am J Kidney Dis. 2014 May;63(5):861-2. doi: 10.1053/j.ajkd.2014.01.424. Epub 2014 Mar 4.